View Post

CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

In Clinical Trials by Barbara Jacoby

News provided by: CytRx Corporation From: This New Trial Represents the Third NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a …

CytRx is pouring money into R&D of cancer-fighting drugs

In In The News by Barbara Jacoby

By Shashank Bengali From: CytRx Corp. is on a mission to cure cancer — or at least slow it down. The Los Angeles biopharmaceutical company, which recently has become embroiled in a stock-promotion controversy, specializes in researching and developing drugs to treat cancers. The most promising medication, aldoxorubicin, is a more advanced version of the widely used chemotherapy drug …